MSN Anti‐Cancer Nanomedicines: Chemotherapy Enhancement, Overcoming of Drug Resistance, and Metastasis Inhibition

He, Qianjun; Shi, Jianlin

doi:10.1002/adma.201303123

Cited by 438 publications

(276 citation statements)

References 173 publications

Supporting

Mentioning

266

Contrasting

Unclassified

Order By: Relevance

“…Compared to monotherapy, the combination therapy also exhibits encouraging results for TNBC, such as enhancing therapeutic efficacy, increasing overall survival rates, and lowering drug dose and side effects 10, 11, 12, 13, 14. For example, Feng et al15 demonstrated that photothermal‐chemotherapy can inhibit the proliferation and lung metastasis of TNBC by using cisplatin–polypeptide wrapped gold nanorods.…”

Section: Introductionmentioning

confidence: 99%

Periodic Mesoporous Organosilica Coated Prussian Blue for MR/PA Dual‐Modal Imaging‐Guided Photothermal‐Chemotherapy of Triple Negative Breast Cancer

Tian

et al. 2016

Advanced Science

View full text Add to dashboard Cite

Complete eradication of highly aggressive triple negative breast cancer (TNBC) remains a notable challenge today. In this work, an imaging‐guided photothermal‐chemotherapy strategy for TNBC is developed for the first time based on a periodic mesoporous organosilica (PMO) coated Prussian blue (PB@PMO) nanoplatform. The PB@PMOs have organic‐inorganic hybrid frameworks, uniform diameter (125 nm), high surface area (866 m2 g−1), large pore size (3.2 nm), excellent photothermal conversion capability, high drug loading capacity (260 µg mg−1), and magnetic resonance (MR) and photoacoustic (PA) imaging abilities. The MR and PA properties of the PB@PMOs are helpful for imaging the tumor and showing the accumulation of the nanoplatform in the tumor region. The bioluminescence intensity and tumor volume of the MDA‐MB‐231‐Luc tumor‐bearing mouse model demonstrate that TNBC can be effectively inhibited by the combined photothermal‐chemotherapy than monotherapy strategy. Histopathological analysis further reveals that the combination therapy results in most extensive apoptotic and necrotic cells in the tumor without inducing obvious side effect to major organs.

show abstract

Section: Introductionmentioning

confidence: 99%

Periodic Mesoporous Organosilica Coated Prussian Blue for MR/PA Dual‐Modal Imaging‐Guided Photothermal‐Chemotherapy of Triple Negative Breast Cancer

Tian

et al. 2016

Advanced Science

View full text Add to dashboard Cite

show abstract

“…Until now, MSNs have been widely investigated to load anticancer drugs for overcoming MDR of cancer cells 130. Similar to other inorganic nanocarriers, the MSNs could efficiently incorporate drugs and effectively deliver them to tumor tissues through the EPR effect.…”

Section: Inorganic Nanocarriers Overcoming Drug Resistance For Cancermentioning

confidence: 99%

Inorganic Nanocarriers Overcoming Multidrug Resistance for Cancer Theranostics

et al. 2016

View full text Add to dashboard Cite

Cancer multidrug resistance (MDR) could lead to therapeutic failure of chemotherapy and radiotherapy, and has become one of the main obstacles to successful cancer treatment. Some advanced drug delivery platforms, such as inorganic nanocarriers, demonstrate a high potential for cancer theranostic to overcome the cancer‐specific limitation of conventional low‐molecular‐weight anticancer agents and imaging probes. Specifically, it could achieve synergetic therapeutic effects, demonstrating stronger killing effects to MDR cancer cells by combining the inorganic nanocarriers with other treatment manners, such as RNA interference and thermal therapy. Moreover, the inorganic nanocarriers could provide imaging functions to help monitor treatment responses, e.g., drug resistance and therapeutic effects, as well as analyze the mechanism of MDR by molecular imaging modalities. In this review, the mechanisms involved in cancer MDR and recent advances of applying inorganic nanocarriers for MDR cancer imaging and therapy are summarized. The inorganic nanocarriers may circumvent cancer MDR for effective therapy and provide a way to track the therapeutic processes for real‐time molecular imaging, demonstrating high performance in studying the interaction of nanocarriers and MDR cancer cells/tissues in laboratory study and further shedding light on elaborate design of nanocarriers that could overcome MDR for clinical translation.

show abstract

“…Then, HeLa cells were incubated with different concentrations of Dox in different formulations at 37°C for 24 or 48 h. As shown in Supplementary Figure S11, the lethality of free Dox at the microgram level was very small due to the effect of ATP-binding cassette transporters acting as drug efflux pumps from the cytoplasm. 37 On the other hand, given the specific targeting by HA and the dual-enzyme controlled drug release, the cellular uptake of Dox-FHMSNs@GNC@HA was higher than that of Dox-FHMSNs@GNC, which led to better anticancer activity.…”

Section: Controlled Drug Release Within the Cells And Selective Toxicitymentioning

confidence: 99%

Peptide-mediated core/satellite/shell multifunctional nanovehicles for precise imaging of cathepsin B activity and dual-enzyme controlled drug release

Zheng

Zhang

et al. 2017

NPG Asia Mater

View full text Add to dashboard Cite

Intracellular imaging of pathologically relevant proteases can provide essential information for the accurate evaluation of disease stage and progression. However, the risks of degradation by nonspecific enzymes during transportation and poor cellular uptake limit the use of peptide-based molecular probes (PMPs) for in situ protease imaging. To overcome these obstacles, a self-protected nanovehicle with a peptide-mediated core/satellite/shell structure was constructed for precise imaging of the protease cathepsin B (Cat B) in situ and the subsequent Cat B-responsive drug release. The self-protected nanovehicles demonstrated excellent resistance to nonspecific enzymolysis, thereby keeping the embedded PMPs intact until they reach the target organelle. Furthermore, the targeting ability of the outer shell facilitated the internalization of nanovehicles into tumor cells via receptor-guided recognition: the protective shell thereafter degraded in the intracellular microenvironment, and Cat B activity was dynamically monitored as the core/satellite structure disassembled. Meanwhile, the peptide-mediated satellite/shell structures served as three-dimensional gatekeepers to lock doxorubicin inside the nanovehicles, and drug release was spatiotemporally controlled by Cat B activity. This study provides important guiding principles for the rational design of self-protected nanovehicles for accurate diagnosis and therapy.

show abstract

MSN Anti‐Cancer Nanomedicines: Chemotherapy Enhancement, Overcoming of Drug Resistance, and Metastasis Inhibition

Cited by 438 publications

References 173 publications

Periodic Mesoporous Organosilica Coated Prussian Blue for MR/PA Dual‐Modal Imaging‐Guided Photothermal‐Chemotherapy of Triple Negative Breast Cancer

Periodic Mesoporous Organosilica Coated Prussian Blue for MR/PA Dual‐Modal Imaging‐Guided Photothermal‐Chemotherapy of Triple Negative Breast Cancer

Inorganic Nanocarriers Overcoming Multidrug Resistance for Cancer Theranostics

Peptide-mediated core/satellite/shell multifunctional nanovehicles for precise imaging of cathepsin B activity and dual-enzyme controlled drug release

Contact Info

Product

Resources

About